BioCryst Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to the design and development of novel, oral small-molecule medicines to treat rare diseases. Founded in 1986 and headquartered in Durham, North Carolina, BioCryst applies structure-based design and crystallography techniques to discover and optimize inhibitors of key enzymes in critical biological pathways. The company’s proprietary platform has generated several leading compounds that have advanced into clinical development and commercialization.
One of BioCryst’s flagship products is peramivir (Rapivab®), an intravenous antiviral therapy for the treatment of acute uncomplicated influenza. Developed through the company’s neuraminidase inhibitor program, peramivir received FDA approval in 2014 and has since been used in hospital settings across the United States, providing a rapid-acting option for patients at risk of influenza complications.
In recent years, BioCryst has expanded its portfolio into the treatment of hereditary angioedema (HAE) with berotralstat (Orladeyo®). Approved by the U.S. Food and Drug Administration in 2020, Orladeyo offers once-daily oral prophylaxis for adults and pediatric patients aged 12 and older. The company continues to pursue regulatory approvals and commercial partnerships to broaden access to Orladeyo in North America, Europe and other markets where HAE therapies are in demand.
Under the leadership of President and Chief Executive Officer Jon Pomeroy, BioCryst remains focused on advancing its pipeline of small-molecule enzyme inhibitors, including candidates targeting complement-mediated disorders and fibrotic diseases. The company maintains research collaborations and manufacturing alliances across the United States and internationally, with the goal of translating its structure-based discovery platform into transformative treatments for underserved patient populations.
AI Generated. May Contain Errors.
Free BCRX Stock Alerts